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ABSTRACT
Background. In renal transplant recipients (RTRs), cardiovas-
cular mortality is the most common cause of long-term renal
graft loss. Oxidative stress (OS) has been associated with cardio-
vascular disease and is known to be enhanced in RTRs. We
aimed to prospectively investigate whether the concentration
of the OS biomarker malondialdehyde (MDA) is associated
with long-term risk of cardiovascular mortality in a large cohort
of RTRs.
Methods. The plasma MDA concentration was measured using
the thiobarbituric acid reaction assay in 604 extensively pheno-
typed RTRs with a functioning allograft for1 year. The associ-
ation between MDA and cardiovascular mortality was assessed
using Cox proportional hazard regression analyses in the overall
cohort and within subgroups according to significant effect
modifiers.
Results. Median circulating MDA concentration at baseline
was 5.38 [interquartile range (IQR) 4.31–6.45] lmol/L. During
a follow-up period of 6.4 (IQR 5.6–6.8) years, 110 (18%) RTRs
died, with 40% of deaths due to cardiovascular causes. MDA
concentration was significantly associated with the risk for car-
diovascular mortality {hazard ratio [HR] 1.31 [95% confidence
interval (CI) 1.03–1.67] per 1-SD increment}, independent of
adjustment for potential confounders, including renal function,
immunosuppressive therapy, smoking status and blood pres-
sure. The association between MDA concentration and the risk
for cardiovascular mortality was stronger in RTRs with relatively
lower plasma ascorbic acid concentrations [42.5mmol/L; HR
1.79 (95% CI 1.30–2.48) per 1-SD increment] or relatively lower
estimated glomerular filtration rates [45mL/min/1.73m2; HR
2.09 (95% CI 1.45–3.00) per 1-SD increment].
Conclusions. Circulating MDA concentration is independently
associated with long-term risk for cardiovascular mortality, par-
ticularly in RTRs with relatively lower ascorbic acid concentra-
tions or renal function. Further studies are warranted to eluci-
date whether OS-targeted interventions could decrease
cardiovascular mortality in RTRs.
Keywords: cardiovascular, malondialdehyde, mortality, oxida-
tive stress, renal transplantation
INTRODUCTION
Although renal transplantation is the best available treatment
for end-stage renal disease [1, 2], improving long-term survival
in renal transplant recipients (RTRs) has proven to be challeng-
ing [3]. The incidence of cardiovascular events among RTRs is
at least twice that in the general population [4] and cardiovascu-
lar disease accounts for 35–50% of deaths [4], thus playing a
leading role [5–7] among the main causes of premature death
in RTRs.
Beyond traditional cardiovascular risk factors, attention has
been focused on complex pathophysiological processes in rela-
tion to chronic renal malfunction [8], including oxidative stress
(OS). OS corresponds to an imbalance between pro-oxidant
species and the antioxidant defence systems, whereby the latter
becomes overwhelmed. OS is increased in end-stage renal dis-
ease and further exacerbated by renal replacement therapies [9].
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It has been associated with atherosclerosis, left ventricular hy-
pertrophy and cardiorenal syndrome [8]. Several mechanisms
have been proposed for the association between OS and athero-
sclerosis: (i) increased OS promotes enzymatic modification of
circulating lipids and lipoproteins [10]; (ii) reactive oxygen spe-
cies (ROS) can directly cause and enhance endothelial dysfunc-
tion [11]; (iii) OS is also known to stimulate the immune
system, which in turn promotes a chronic pro-inflammatory
status and (iv) OS promotes osteoblastic differentiation of vas-
cular cells [12]. However, to date, there are no prospective stud-
ies investigating a plausible association between post-transplant
OS and the risk for cardiovascular mortality in RTRs. Plasma
malondialdehyde (MDA) is the principal and best investigated
product of lipid peroxidation, one of the main reactions caused
by enhanced OS [13], and has been widely used as an OS bio-
marker in several clinical settings, including in the study of kid-
ney disease patients [14–16].
In the current study, we aimed to test prospectively the hy-
pothesis that plasma MDA concentration is associated with
the long-term risk for cardiovascular mortality in RTRs. In
addition, we aimed to evaluate whether a putative association
between plasmaMDA concentration and the risk for cardiovas-
cular mortality in RTRs may be modified by traditional cardio-
vascular risk factors and oxidative status-associated biomarkers.
MATERIALS AND METHODS
Study design
In this prospective cohort study, all adult RTRs with a func-
tioning allograft of 1 year and without known or apparent
systemic illnesses who visited the outpatient clinic of the
University Medical Center of Groningen (The Netherlands)
were suitable for inclusion. Between August 2001 and July
2003, 847 RTRs were invited for enrolment in the study, of
whom 606 (72%) provided informed written consent. We ex-
cluded patients lacking plasma MDA measurements (n¼ 2),
thus resulting in 604 RTRs, whose data are presented here. This
study was approved by the institutional review board (METc
2001/039) and in accordance with the Declarations of Helsinki
and Istanbul.
The endpoint of the study was cardiovascular morality.
A continuous surveillance system as part of the outpatient pro-
gramme and close collaboration with affiliated hospitals en-
sured up-to-date information on patient status. We contacted
general practitioners or referring nephrologists in cases
where the patient status was unknown. There was no loss to fol-
low-up.
Patients characteristics
Relevant donor, recipient and transplant characteristics were
extracted from the Groningen Renal Transplant Database,
which has been previously described in detail [16]. Data on ste-
roid dosages, use of other immunosuppressive medications
and incidence of acute rejection were retrieved from individual
patient files.
Measurements and definitions
Anthropometric measurements were taken with participants
wearing indoor clothing, with no shoes on.Waist circumference
was measured on bare skin midway between the iliac crest and
the tenth rib and blood pressure was measured as the average of
three measurements taken at 1-min intervals after a 6-min rest
in the supine position using an automated device (Omron M4,
Omron Europe, Hoofddorp, The Netherlands).
According to a strict protocol, all RTRs collected a 24-h urine
sample during the day before to their visit to the outpatient
clinic and all patients provided a blood sample in the morning
after an 8- to 12-h overnight fasting period, which included no
medication intake. Plasma MDA is considered a preferred bio-
marker of OS since lipids are the main target of OS and MDA is
the principal and best-investigated product of lipid peroxida-
tion [13, 17]. Also, it has been widely used as a marker of OS in
several pathological states, including kidney disease [14–16].
MDA concentration was determined using the following
method. Thiobarbituric acid was used to bind MDA, forming
Thiobarbituric acid reaction species (TBARS), which were then
extracted in a butanol layer and measured using a fluorescence
spectrophotometer at 485/590 nm (FL600, Beun de Ronde,
Abcoude, The Netherlands). This method has a reported intra-
assay coefficient of variation of 6.0% [18]. Serum creatinine
concentrations were determined by the Jaffe´ method (MEGA
AU510, Merck Diagnostica, Darmstadt, Germany) and ascorbic
acid concentrations were measured by reverse-phase liquid
chromatography with fluorescence detection, as previously de-
scribed in detail [19].
Estimated glomerular filtration rate (eGFR) was calculated
by applying the Chronic Kidney Disease Epidemiology
Collaboration equation [20] and the cumulative dose of pred-
nisolone was calculated as the sum of the maintenance dose of
prednisolone until study inclusion and the dose of prednisolone
or methylprednisolone required for treatment of acute rejection
(a conversion factor of 1.25 was used to convert the dose of
methylprednisolone to that of prednisolone).
Proteinuria was defined as urinary protein excretion of
>0.5 g in 24 h. Cardiovascular disease history was considered
positive if participants had a myocardial infarction, transient
ischaemic attack or cerebrovascular accident.
The cause of death was obtained by linking the number of
the death certificate to the primary cause of death as coded by a
physician from the Central Bureau of Statistics according to the
International Classification of Diseases, Ninth Revision (ICD-
9) [21]. Cardiovascular death was defined as the principal cause
of death being cardiovascular in nature (ICD-9 codes 410–447).
Statistical analysis
Data were analysed using SPSS software version 23.0 (IBM,
Armonk, NY, USA), Stata 14.1 (StataCorp, College Station, TX,
USA) and R version 3.2.3 (R Foundation, Vienna, Austria). In
all analyses, a two-sided P-value<0.05 was considered signifi-
cant, except for the effect modification analyses, where the sig-
nificance level was P< 0.10 [22]. Continuous variables were
summarized using the mean 6 standard deviation (SD) for
normally distributed data, median [interquartile range (IQR)]
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for skewed distributed variables and percentages for categorical
variables. In order to determine in an integrated manner which
baseline variables were independently associated with circulat-
ing MDA concentration, we performed crude linear regression
analyses and then adjusted for age and sex and finally for eGFR.
The stronger determinants of plasma MDA were selected by
stepwise backward multivariable linear regression analysis. For
inclusion and exclusion, P-values were set at 0.20 and 0.05,
respectively.
To analyse whether plasma MDA concentration was inde-
pendently associated with the risk for cardiovascular mortality,
we performed Cox proportional hazards regression analyses.
First, we performed a univariate analysis with MDA concentra-
tion as a continuous variable (Model 1). Thereafter we adjusted
for age, sex, eGFR, time since transplantation and proteinuria
status (Model 2). To avoid inclusion of too many variables for
the number of events, further models included additive adjust-
ments to Model 2. We performed additional adjustments for
the traditional cardiovascular risk factors according to the
Framingham risk score: smoking status, total cholesterol, high-
density lipoprotein (HDL) cholesterol, systolic blood pressure
(SBP) and antihypertensive drug use (Model 3); for cardiovas-
cular risk factors proposed by the World Health Organization
(WHO), including diabetes mellitus, obesity according to the
WHO and waist circumference 102 cm in males and 88 cm
in females (Model 4); for cardiovascular history, including previ-
ous cardiovascular events and use of statins (Model 5); and for
immunosuppressive therapy, including cumulative prednisolone
dose and donor status (Model 6). In order to account for non-
cardiovascular mortality when assessing cardiovascular mortal-
ity, we performed competing risk analyses by fitting cause-
specific multivariable-adjusted Cox proportional hazard models.
In each of these models, the competing events are treated as cen-
sored observations [23]. Models were checked for fulfilment of
the assumptions for linear regression and Cox regression and all
assumptions were met. Hazard ratios (HR) are reported per 1-
SD increment increase and with 95% confidence interval (CI).
Furthermore, we performed pre-specified effect modifica-
tion analyses in which we tested known cardiovascular risk fac-
tors (e.g. eGFR, proteinuria, diabetes mellitus, smoking status)
or variables associated with oxidative status (e.g. plasma ascor-
bic acid concentration). For these analyses, we used multiplica-
tive interaction terms. In cases of significant effect modification,
we proceeded with stratified prospective analyses for the con-
cerned variable. Cut-off points for originally continuous varia-
bles used in the stratified analyses were determined, so they
would allow a similar number of events in each category and
statistical power would be maximized. Stratified prospective
analyses were adjusted for age, sex, eGFR and SBP.
RESULTS
Baseline characteristics and association with plasma
MDA concentration
A total of 604 stable RTRs were included (mean age
516 12 years, 55% male, 96% Caucasian), at a median of 6.0
(IQR 2.7–11.5) years after transplantation. Baseline
characteristics of the overall RTR population are shown in
Table 1. The median plasma MDA concentration at baseline
was 5.38 (IQR 4.31–6.45) mmol/L. Regarding graft function, the
mean eGFR was 476 16mL/min/1.73m2 and 28% of partici-
pants had proteinuria. As for known cardiovascular risk factors,
16% of patients had obesity and 52% had a waist circumference
greater than the threshold proposed by the WHO. Mean SBP
was 1536 23mmHg and 87% of patients were on antihyper-
tensive medication. Twenty per cent of patients were current
smokers and diabetes mellitus was present in 18% of patients.
Finally, 12% of patients had a previous cardiovascular event
and half of the patients were receiving statins.
In crude linear regression analyses, plasma MDA concentra-
tion was significantly and directly associated with waist circum-
ference [standardized b coefficient (Std b)¼ 0.10; P¼ 0.01]
and inversely associated with the use of angiotensin-converting
enzyme (ACE) inhibitors or angiotensin II receptor blockers
(ARBs) (Std b¼0.10; P¼ 0.01). Measurements of renal func-
tion, such as plasma urea concentration (Std b ¼ 0.10;
P¼ 0.02), eGFR (Std b¼ 0.14; P< 0.01) and proteinuria (Std b
¼ 0.09; P¼ 0.03), were also significantly associated with
plasma MDA concentration. Among transplant-related charac-
teristics, time since transplantation (Std b ¼ 0.12; P< 0.01)
and cumulative prednisolone dose (Std b ¼ 0.14; P< 0.01)
were also both significantly and inversely associated with
plasma MDA concentration. After adjustment for age and sex,
waist circumference was no longer significantly associated with
circulating MDA concentration. Posterior adjustment for renal
function revealed direct significant association between circu-
lating MDA concentration and age (Std b¼ 0.10; P¼ 0.02), di-
astolic blood pressure (Std b¼ 0.09; P¼ 0.03) and total
cholesterol (Std b¼ 0.08; P¼ 0.04), whereas proteinuria was no
longer significantly associated. A final model obtained by linear
regression with backward selection (a¼ 0.05; b¼ 0.20) found
sex, waist circumference, use of ACE inhibitors/ARBs, eGFR,
donor type (living or deceased), cumulative prednisolone dose,
total cholesterol, high-sensitivity C-reactive protein (hs-CRP),
Ne-(carboxymethyl)lysine and intercellular adhesion molecule-
1 as the stronger determinants of circulating MDA concentra-
tion (Table 1).
Prospective analyses
During a median follow-up of 6.4 (IQR 5.6–6.8) years, 110
(18%) RTRs died, with 44 (40%) deaths due to cardiovascular
causes. Prospective analyses showed that plasma MDA concen-
tration was directly associated with the risk for cardiovascular
mortality [HR 1.31 (95% CI 1.03–1.67) per 1-SD increment;
P¼ 0.03]. This association was independent of adjustment for
potential confounders, with, for example, an HR of 1.39 (95%
CI 1.05–1.83) per 1-SD increment after adjustment for age, sex,
eGFR, time since transplantation and proteinuria status.
Further adjustment for the cardiovascular risk factors listed in
the Framingham score and those proposed by the WHO,
patients cardiovascular history and immunosuppressive therapy
did not materially alter the association (Table 2). Competing risk
analyses showed that MDA concentration, although consistently
associated with cardiovascular mortality, was not associated with
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Table 1. Baseline characteristics of the study population (N¼ 604) and their association with circulating MDA concentration









Std. b Std. b Std. b Std. b
Plasma MDA concentration (mmol/L), median (IQR) 5.38 (4.31–6.45) – – – –
Demographic and body composition
Age (years), mean6 SD 516 12 0.08* 0.08* 0.10** 0.11**
Sex (male), n (%) 331 (55) 0.07* 0.07* 0.06* 0.12**
Caucasian ethnicity, n (%) 582 (96) 0.003 0.01 0.003
Body mass index (kg/m2), mean6 SD 26.046 4.29 0.03 0.03 0.03
Body mass index 30 kg/m2, n (%) 96 (16) 0.07* 0.07* 0.07* –e
Waist circumference (cm)f, mean6 SD 976 14 0.10** 0.07* 0.09* 0.16**
Waist circumference 102 cm (M)/88 cm (F), n (%)f 316 (52) 0.03 0.02 0.03
Cardiovascular history
History of cardiovascular disease, n (%)g 75 (12) 0.04 0.06* 0.05
Systolic blood pressure (mmHg), mean6 SD 1536 23 0.01 0.02 0.02
Diastolic blood pressure (mmHg), mean6 SD 906 10 0.06* 0.07* 0.09** –e
Use of ACE inhibitors or ARBs, n (%) 202 (33) 0.10** 0.11** 0.10** 0.14**
Use of b-blockers, n (%) 374 (62) 0.00 0.001 0.01
Use of calcium channel antagonists, n (%) 230 (38) 0.06* 0.06* 0.06* –e
Use of statins, n (%) 300 (50) 0.04 0.05 0.04
Current smoker, n (%) 133 (22) 0.06* 0.05 0.04
Renal allograft function
eGFR (mL/min/1.73m2), mean6 SD 476 16 0.14** 0.15** – 0.24**
Proteinuria 0.5 g/24 h, n (%)h 168 (28) 0.09** 0.09** 0.06* –e
Plasma urea (mmol/L), median (IQR) 9.50 (7.20–13.18) 0.10** 0.12** 0.01
Renal transplant and immunosuppressive therapy
Living donor, n (%) 83 (14) 0.08* 0.06* 0.07* 0.13**
Time since transplantation (years), median (IQR) 6.0 (2.7–11.5) 0.12** 0.13** 0.15** –e
Cumulative prednisolone dose (g), median (IQR) 21.35 (11.38–37.97) 0.14** 0.15** 0.16** 0.18**
Sirolimus or rapamune use, n (%) 10 (2) 0.001 0.001 0.01
Type of calcineurin inhibitor 0.06* 0.07* 0.08* –e
Ciclosporin, n (%) 389 (64)
Tacrolimus, n (%) 84 (14)
Type of proliferation inhibitor 0.03 0.04 0.03
Azathioprine, n (%) 198 (33)
Mycophenolic acid, n (%) 249 (41)
Acute rejection treatment, n (%) 332 (55) 0.08* 0.08* 0.06* –e
Metabolic parameters
Total cholesterol (mmol/L), median (IQR) 5.59 (4.92–6.19) 0.08* 0.08* 0.08** 0.09*
High-density lipoprotein cholesterol (mmol/L), median (IQR) 1.05 (0.86–1.28) 0.03 0.05 0.02
Low-density lipoprotein cholesterol (mmol/L), median (IQR) 3.53 (2.93–4.12) 0.06* 0.06* 0.06* –e
Triglycerides (mmol/L), median (IQR) 1.92 (1.40–2.64) 0.03 0.03 0.04
HbA1c (%)f, mean6 SD 6.526 1.06 0.04 0.02 0.05
Diabetic subjects, n (%) 106 (18) 0.01 0.02 0.02
OS and inflammatory parameters
hs-CRP (mg/L), median (IQR) 2.04 (0.79–4.82) 0.05 0.05 0.07* 0.16**
Plasma ascorbic acid (mmol/L)i, mean6 SD 44.496 20.00 0.003 0.02 0.004
CML (mmol/L), median (IQR) 1.79 (1.47–2.09) 0.05 0.05 0.13* 0.18**
ICAM-1 (ng/L), median (IQR) 603 (513–722) 0.06* 0.07* 0.06* 0.14**
*P< 0.20; **P< 0.05.
aCrude linear regression analysis.
bLinear regression analysis adjusted for age and sex.
cLinear regression analysis adjusted for age, sex, and eGFR.
dStepwise backward linear regression analysis; for inclusion and exclusion in this analysis, P-values were set at 0.2 and 0.05, respectively.
eExcluded from the final model.
fData available in 603 patients.
gData available in 600 patients.
hData available in 602 patients.
iData available in 596 patients.
HbA1c, glycated haemoglobin; CML, Ne-(carboxymethyl)lysine; ICAM-1, intercellular adhesion molecule-1.
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the competing event non-cardiovascular mortality, and posterior
adjustments did not alter this result (Table 2).
Effect modification analyses
In effect modification analyses, we found that the association
between MDA concentration and the risk for cardiovascular
mortality was significantly modified by plasma ascorbic
acid concentration and eGFR (Pinteraction< 0.001 and
Pinteraction¼ 0.09, respectively). Other variables such as use of
ACE inhibitors/ARBs, plasma urea concentration and cumula-
tive prednisolone dose were not significant effect modifiers
(Supplementary Table S1). Next we performed stratified pro-
spective analyses by subgroups of RTRs according to categories
of plasma ascorbic acid concentration ( or>42.5mmol/L) and
eGFR ( or>45mL/min/1.73m2). Cut-off points were selected
so there was a similar number of events in each subgroup.
The positive association between plasma MDA concentra-
tion and the risk for cardiovascular mortality was stronger
among patients with relatively lower concentrations of ascorbic
acid [HR 1.79 (95% CI 1.30–2.48) per 1-SD increase; P< 0.001]
compared with the overall population. Moreover, among RTRs
with relatively higher ascorbic acid concentrations, the associa-
tion between plasma MDA concentration and the risk for car-
diovascular mortality was no longer significant [HR 0.85 (95%
CI 0.52–1.40) per 1-SD increase; P¼ 0.53]. Likewise, the posi-
tive association between plasma MDA concentration and the
risk for cardiovascular mortality was stronger among patients
with relatively lower eGFR [HR 2.09 (95% CI 1.45–3.00) per 1-
SD increase; P< 0.001] compared with the overall RTR popula-
tion (Figure 1).
In sensitivity analyses we explored the effect modification of
plasma ascorbic acid concentration by using the cut-off point
for plasma ascorbic acid depletion ( or >28mmol/L) [19]. In
agreement with previous results, within the vitamin C–depleted
subgroup of RTRs, the hazard ratios for the association of
plasma MDA concentration with the risk for cardiovascular
mortality were stronger [HR 2.58 (95% CI 1.63–4.01) per 1-SD
increment; P< 0.001] compared with the overall analyses, as
well as stronger compared with the previous vitamin C–strati-
fied analyses. Also, in the non-vitamin C–depleted subgroup
of RTRs, no significant association was found between circulat-
ing MDA concentration and cardiovascular mortality risk
(Supplementary Table S2).
DISCUSSION
This study showed that relatively higher plasma MDA concen-
trations are independently associated with a higher risk for car-
diovascular mortality in RTRs. We also found that this
association was modified by circulating ascorbic acid concen-
tration, with a stronger association between MDA concentra-
tion and cardiovascular mortality risk among patients with
relatively lower concentrations of ascorbic acid. Graft function
measured in terms of eGFR was also a significant effect modi-
fier, with a stronger association among patients with Kidney
Disease: Improving Global Outcomes G3b, G4 and G5 stages of
chronic kidney disease. Our findings are in agreement with sev-
eral studies showing an association between OS and the patho-
physiology of several cardiovascular diseases [8, 10–12].
However, to the best of our knowledge, this is the first study
assessing the relationship between plasma MDA concentration
and the risk for cardiovascular mortality in the post-renal trans-
plantation setting.
ROS are important mediators of cellular damage, with lipid
peroxidation as a major manifestation of ROS-induced OS [13].
Circulating MDA concentration is one of the most commonly
used biomarkers for this phenomenon [24]. Also, MDA itself is
a toxic molecule, since it is highly reactive against a variety of
biomolecules, including nucleic acids and proteins, and often
leads to irreversible damage to important cellular structures
[13]. An increase in OS, and consequently in MDA concentra-
tion, is known to be persistent through end-stage renal disease,
in part due to decreased urinary clearance and also in part due
to the chronic pro-inflammatory state that is characteristic of
end-stage renal disease [25]. Post-renal transplantation, this im-
balance is only incompletely corrected [26], in part because
maintenance immunosuppressive drugs stimulate the produc-
tion of oxygen radicals and lipid peroxidation [27, 28].
OS is associated with several pathophysiological mecha-
nisms that explain the high incidence of cardiovascular events
in renal patients [29]. Increased OS promotes endothelial dys-
function by decreasing the bioavailability of nitric oxide [10]
and disturbs the regulatory function of HDL in atherosclerosis
through promotion of HDL oxidation [30]. OS also increases
calcium deposition in atherosclerotic plaques, as it acts as a pos-
itive signal for osteoblastic differentiation of vascular cells [12].
MDA also reacts with primary amines, thereby modifying the
apoB fractions of oxidized low-density lipoprotein (LDL),
which makes oxidized LDL a target for uptake by macrophages
[13]. Consistent with this evidence, clinical studies in end-stage
renal disease showed a correlation between higher circulating
MDA concentrations and the severity of coronary artery disease
[31]. Furthermore, OS has been associated with left ventricular
Table 2. Multivariable-adjusted associations between plasma MDA con-
centration and cardiovascular mortality risk in 604 RTRs
Models HR per 1-SD increment 95% CI P-value
Cardiovascular mortality
Model 1 1.31 1.03–1.67 0.03
Model 2 1.39 1.05–1.83 0.02
Model 3 1.43 1.11–1.85 0.01
Model 4 1.39 1.04–1.85 0.02
Model 5 1.40 1.06–1.85 0.02
Model 6 1.41 1.06–1.88 0.02
Non-cardiovascular mortality
Model 1 1.13 0.90–1.41 0.31
Model 2 1.14 0.88–1.49 0.33
Model 3 1.18 0.92–1.52 0.19
Model 4 1.12 0.89–1.51 0.28
Model 5 1.12 0.86–1.45 0.42
Model 6 1.16 0.89–1.52 0.27
In total, 110 (18%) patients died, of which 44 (40%) deaths were due to cardiovascular
causes. Model 1: crude model. Model 2: Model 1þ adjustment for age, sex, time since
transplantation, eGFR and proteinuria status. Model 3: Model 2þ adjustment for car-
diovascular risk factors included in the Framingham score. Model 4: Model
2þ adjustment for cardiovascular risk factors proposed by the WHO. Model 5: Model
2þ adjustment for cardiovascular history. Model 6: Model 2þ adjustment for type of
donor and immunosuppressive therapy.
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hypertrophy and stiffening through increased cardiac fibroblas-
tic differentiation, with MDA promoting intermolecular colla-
gen cross-linking [8, 13]. MDA also inhibits the contractile
function of cardiac myocytes and enhances the cardiorenal syn-
drome by activating inflammatory nuclear factor jB pathways
[11, 32]. Extrapolating these data, we found an association be-
tween circulating MDA concentration and the risk for cardio-
vascular mortality in RTRs, which provides the first
longitudinal evidence in the post-renal transplantation clinical
setting.
In this study, plasma ascorbic acid concentration and renal
function were both found to be significant and consistent effect
modifiers. Vitamin C is an important antioxidant in biological
fluids, including plasma [33], and one of the most important
antioxidant nutrients, obtained exclusively from dietary sources
[34]. Thus it is not surprising that the overall association be-
tween plasma MDA concentration and cardiovascular mortal-
ity risk was particularly strong among RTRs with relatively
lower plasma ascorbic acid concentrations or those who were
vitamin C–depleted. More interesting is the fact that no signifi-
cant association was found among RTRs with relatively higher
plasma ascorbic acid concentrations or those who were not vita-
min C–depleted, which raises the question of whether vitamin
C–directed interventions could be of use as a strategy for
decreasing cardiovascular mortality. Further support to our
findings comes from recent evidence showing that ascorbic acid
depletion is independently associated with all-cause mortality
in RTRs [19].
As for the effect modification of eGFR, a large body of evi-
dence confers a causative role to OS in the underlying mecha-
nisms leading to renal disease. Several inducers of kidney
damage have been shown to induce renal OS [35–38] and kid-
ney tissue is known to be highly vulnerable to OS damage
because it is abundant in long-chain polyunsaturated fatty acids
[39]. It has been hypothesized that in the kidney exists a
feedback cycle whereby OS is increased by renal impairment
and increased OS, which in turn, further impairs renal function
[8, 40, 41].
Therapeutic reduction of OS is a matter of interest and it can
be achieved by lowering exposure to environmental oxidative
molecules, by decreasing the generation of OS through
stabilization of mitochondrial function and by increasing the
levels of endogenous and exogenous antioxidants (e.g. vitamin
C, vitamin E and N-acetylcysteine), with the latter being the
most widely used approach [42–44]. It should be noted that a
Cochrane review conducted in 2012 could not conclude a clear
benefit of antioxidant supplementation therapies in reducing
cardiovascular mortality in patients with kidney disease, al-
though this was attributed to suboptimal quality of available
studies and a lack of sufficiently powered studies [45, 46]. Our
results, including the effect modification of plasma concentra-
tion of ascorbic acid, underline the need for a better under-
standing of the impact of OS on high cardiovascular risk and
premature cardiovascular mortality after renal transplantation.
Our findings also highlight the need for further studies to
explore the potential role of antioxidants in reducing the long-
standing burden of cardiovascular mortality in the RTR
population.
The current study comprises a large cohort of stable and
extensively phenotyped RTRs, which allowed adjustment for
several potential confounders. Furthermore, all study subjects
were closely monitored through the vigilance system in place at
our outpatient clinic and affiliated hospitals, thus ensuring
complete information on patient status was collected, with no
loss to follow-up. On the other hand, we acknowledge certain
weaknesses of the study. First, this is a single-centre study with
a study population almost entirely composed of white subjects,
which calls for prudence when extrapolating our findings to
other populations with regard to different ethnicities. Second,
like most epidemiological studies, the current study used a sin-
gle baseline measurement to predict outcomes, which adversely
impacts the predictive properties of variables associated with
outcomes. If intra-individual variability of predictive bio-
markers using repeated measurements is taken into account,
this results in strengthening of predictive properties, particu-
larly in the case of markers with high intra-individual variability
[47–49]. Third, although we used the most common method
for determining MDA concentration, the thiobarbituric acid re-
action assay is not exclusively specific for MDA and can detect
other lipid peroxidation aldehydes. Next, as with any observa-
tional study, our study cannot unequivocally distinguish
whether there is a causal link between MDA concentration and
FIGURE 1: Stratified analysis of the association of MDA concentration with cardiovascular mortality, according to significant effect modifiers,
in RTRs. HRs and 95% CIs were calculated with adjustment for age, sex, eGFR and SBP.
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cardiovascular mortality risk or whether MDA is merely a
marker of higher risk for cardiovascular mortality. However,
currently available evidence regarding MDA biology supports a
pathophysiological link between MDA and cardiovascular dis-
ease [29]. Finally, as with any observational study, unmeasured
confounding may still occur, despite adjusting for a substantial
number of potentially confounding variables in our analyses.
In conclusion, in stable RTRs, plasmaMDA concentration is
independently associated with long-term risk for cardiovascular
mortality. This is the first study providing data that prospec-
tively associate OS with a long-term survival endpoint in the
post-renal transplantation setting. This evidence provides a ra-
tionale for further studies to explore potential OS-targeted ther-
apeutic/nutritional treatments aimed to improve long-term
cardiovascular outcomes in RTRs.
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ABSTRACT
Background. Renal dysfunction is a serious late complica-
tion after liver transplantation (LTX), but there are no
studies addressing the early changes associated with this
complication.
Methods. We prospectively studied glomerular filtration rate
(GFR) before and at 1, 3 and 12weeks after LTX using 51Cr-la-
belled ethylenediaminetetraacetic acid clearance in 37 adult
consecutive patients who underwent non-acute first LTX.
Results. The mean (6SD) age was 49.56 9.5 years, and the
male:female sex ratio was 21:16. Diagnoses were
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